CyBorD: Stellar response rates in AL amyloidosis

Blood

Volumn 119, Issue 19, 2012, Pages 4343-4345

  Merlini, Giampaolo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMYLOID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN;

AMYLOIDOSIS; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DISEASE SEVERITY; HUMAN; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; NEUROPATHY; NOTE; PERIPHERAL NERVOUS SYSTEM; PLASMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; TREATMENT RESPONSE;

EID: 84860895856     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-413112     Document Type: Note

References (12)

1. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide- bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
2. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012; 119(19):4387-4390.
3. Perfetti V, Palladini G, Casarini S, et al. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119(1):144-150.
4. Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010;107(9):4188-4193.
5. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. (Pubitemid 41095215)
6. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430.
7. Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-1122.
8. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-2445. (Pubitemid 36605226)
9. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008;143(3):369-373.
10. Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-528.
11. Gasparetto C, Sanchorawala V, Snyder RM, et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis [abstract]. J Clin Oncol (Meeting Abstracts). 2010;28(15 suppl):8024.
12. Palladini G, Dispenzieri A, Gertz MAA, et al. Validation of the criteria of response to treatment In AL amyloidosis [lsqb[abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1364.